Bioburden

Bioburden describes the population of viable microorganisms present in raw materials, process intermediates, or finished products prior to sterilisation. It represents a critical microbiological quality attribute that influences sterility assurance, filtration performance, and overall contamination risk in biopharmaceutical manufacturing. Bioburden is typically measured through validated microbial enumeration methods and expressed as colony forming units per volume or per unit of material.

The biopharmaceutical industry monitors bioburden to maintain control of microbial contamination throughout production, particularly for sterile drug products and aseptic processing operations. Elevated bioburden can compromise sterile filtration, increase endotoxin risk, and trigger deviations requiring investigation and corrective actions. Manufacturers implement robust control strategies including raw material qualification, environmental monitoring, sanitisation programmes, and closed processing systems to minimise microbial ingress. Regulatory agencies expect bioburden limits to be scientifically justified, consistently achieved, and supported by trending data that demonstrates ongoing process control and facility hygiene performance.